- Trial phase
- Preclinical
- Time to market
- Several years away, if ever. MiNK-215 remains in preclinical research with no IND filed or clinical trial initiated. An investigational new drug (IND) application and Phase 1 trial initiation would be the next milestones, which typically require 1-2 years of additional preclinical work plus regulatory review.
- Why 2/10
- MiNK-215 is a preclinical-stage program with no scheduled PDUFA date, pivotal readout, or IND filing catalyst in the next ~12 months. The company's near-term value is driven by its lead asset agenT-797 (Phase 2 ARDS trial, data expected 2H2027). As a small preclinical program at a cash-constrained clinical-stage company, MiNK-215 alone is unlikely to drive a material stock move in the forecast window.
MiNK-215 is a preclinical asset with no near-term binary catalyst. Watch for any IND filing or first-in-human clinical trial initiation, which could take 12-24 months. The stock's near-term value driver remains the Phase 2 ARDS trial of agenT-797 (data expected 2H2027).
Price Chart
Executive Summary
MiNK-215 is an investigational, allogeneic (off-the-shelf) CAR-iNKT cell therapy from MiNK Therapeutics (INKT) that targets fibroblast activation protein (FAP) on tumor-supporting stromal cells and incorporates IL-15 for enhanced persistence. It is a preclinical-stage asset with no clinical trials initiated. Preclinical data presented at AACR 2024 and SITC 2026 (November 2026) showed senolytic activity clearing chemotherapy-resistant senescent cells and anti-tumor activity in colorectal cancer liver metastasis models. MiNK-215 is a small component of MiNK's pipeline; the company's lead program is agenT-797, currently in a randomized Phase 2 trial for acute respiratory distress syndrome (ARDS) with data expected in the second half of 2027. As a preclinical program at a cash-constrained ($7.5M) clinical-stage biotech, MiNK-215 has no near-term binary catalyst and is unlikely to drive a material stock move on its own.
How It Works
MiNK-215 is an engineered immune cell therapy. It takes donor-derived invariant natural killer T (iNKT) cells and adds two features: a homing receptor (CAR) that targets a protein called FAP found on supportive cells (fibroblasts) inside tumors, and a growth factor (IL-15) to help the cells survive longer. The therapy is given as a ready-made, off-the-shelf infusion, skipping the personalized manufacturing needed for CAR-T therapies. It is designed to break down the protective barrier tumors build and kill senescent (aged, damaged) cells that chemotherapy leaves behind.
Trial Status
MiNK-215 is in preclinical development. In vitro and in vivo preclinical data have been presented at AACR 2024 and SITC 2026 demonstrating FAP-targeted CAR activity, IL-15-enhanced persistence, and senolytic effects. No clinical trials have been initiated or registered on ClinicalTrials.gov as of November 2026.
The Two-Sided Case
Upcoming Catalysts
- No near-term catalysts specific to MiNK-215. The program would need an IND filing and Phase 1 trial initiation to become a clinical-stage asset; no timeline has been announced.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MiNK Therapeutics PRESS-RELEASE INKT ·Originating report